Medical News Bulletin - Daily Medical News, Health News, Clinical Trials And Clinical Research, Medical Technology, Fitness And Nutrition News–In One Place

Cancer remains one of the leading global health challenges. A huge reason behind this is the unique molecular and genetic characteristics of various cancers that make it difficult to treat. You can have two patients with the same type of cancer responding differently to treatment.  It’s the reason why traditional therapies and generalized treatment methods […]

The post How Precision Medicine and Small Molecule Research Are Improving Modern Cancer Care appeared first on Medical News Bulletin.

The FDA granted orphan drug designation and fast track designation to Lacripep, according to a press release from TearSolutions. If approved, Lacripep would be the second treatment indicated for neurotrophic keratitis.
In addition, the first patients have been dosed in a phase 2 multicenter, randomized clinical trial of Lacripep, the company said.
The topical therapy is a synthetic peptide made from “a naturally occurring fragment” of lacritin, a human tear protein, according to TearSolutions.
“Lacripep regenerates certain cell types like the corneal epithelium and corneal sensory nerves,”

Use of AI-enhanced ECGs and electronic health records enabled researchers to distinguish people at high risk for out-of-hospital cardiac arrest, according to data published in JACC: Advances.
“There to date remains no established, validated approach for cardiac arrest screening in the general population,” Neal Chatterjee, MD, MSc, associate professor of medicine at the University of Washington School of Medicine, told Healio. “Our work highlights a couple of things. No. 1, the factors that are driving cardiac arrest risk, to some extent, are cardiovascular, but there’s a large amount of that

CHICAGO — Patient-facing resources about AI in cancer care are scarce, according to study results presented at ASCO Annual Meeting.
They often are poor quality and written at a reading level far above average for the U.S. population, researchers found.
They also lack information about critical safety risks related to AI — such as misinformation — that should be highlighted for patients navigating a new and complex diagnosis, Pearl Subramanian, MD, second-year internal medicine resident at University of Pennsylvania’s Abramson Cancer Center and Perelman School of Medicine, and colleagues

More than one-third of U.S. adults recently experienced a sunburn, and more than 55% reported their most recent sunburn occurred while using sunscreen, according to the CDC’s Morbidity and Mortality Weekly Report.
According to the CDC’s 2024 National Health Interview Survey, 35.1% of adults in the United States — 88.1 million people — have experienced a sunburn during the previous year. Of this total, 7.5% reported four or more sunburns. These figures are alarming and should spur action from health care professionals, according to Dawn M. Holman, MPH, behavioral scientist in the division of

Low-insulinemic and plant-based diets were tied to the lowest amount of weight gain for women during menopause, according to findings published in JAMA Network Open.
“Midlife represents a critical yet often overlooked window for dietary counseling and chronic disease prevention,” Frank B. Hu, MD, PhD, MPH, chair of the department of nutrition at the Harvard T.H. Chan School of Public Health; Tong Xia, MD, PhD, MPH, postdoctoral research fellow at Brigham and Women’s Hospital; and Cuilin Zhang, MD, PhD, MPH, director of the Global Centre for Asian Women’s Health at National University of

Rural counties in the U.S. are experiencing increasing rates of hepatocellular carcinoma incidence and mortality while urban areas are seeing declines, according to study results published in JAMA Network Open.
Rural non-Hispanic white populations showed the sharpest rises in HCC incidence and mortality.
“The widely reported national decline in HCC incidence does not mirror the situation in many rural communities,” study author Tarik Demir, MD, gastrointestinal medical oncologist at The Ohio State University Comprehensive Cancer Center – James, told Healio. “Although urban areas have seen

The FDA has approved a label expansion for the interleukin-23 inhibitor guselkumab to include the inhibition of structural joint damage progression in adults with psoriatic arthritis.
The label update follows data from the APEX trial, in which guselkumab (Tremfya, Janssen) yielded significantly lower rates of radiographic progression compared with placebo at 24 weeks. The analysis, which was published by Philip J. Mease, MD, of Swedish Medical Center and the University of Washington, and colleagues in the Annals of the Rheumatic Diseases in December, included more than 1,000 biologic-naïve